Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31Prostatic Hyperplasia 5Neoplasms 4Urinary Bladder Neoplasms 1Recurrence 1Neoplasm Metastasis 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Adenocarcinoma of the Prostate 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Dutasteride × Genitourinary × Clear all
NCT01393730 2018-03-15

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
40 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡